Drug Search Results
More Filters [+]

Glesatinib

Alternative Names: glesatinib, mgcd265
Latest Update: 2024-04-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: RTK Inhibitor,C-Met Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Glesatinib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer

Phase 1: Small Cell Lung Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Head and Neck Cancer|Oncology Unspecified|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MRTX-500

P2

Terminated

Non-Small-Cell Lung Cancer

2021-11-04

2015-002070-21

P2

Completed

Non-Small-Cell Lung Cancer

2019-01-02

NCT00697632

P1

Completed

Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma|Head and Neck Cancer

2018-09-01

29%

NCT02544633

P2

Completed

Non-Small-Cell Lung Cancer

2018-04-30

Recent News Events